HX044

HX044 is a first-in-class bispecific antibody developed by Hanx Biopharmaceuticals. It targets both CD47 and cytotoxic T-lymphocyte–associated antigen 4 (CTLA4), functioning as a CD47 agonist and CTLA4 inhibitor. This next-generation immune-checkpoint inhibitor is designed to treat a broad range of malignant tumors, including those resistant to programmed death 1 (PD-1) inhibitors such as non-small cell lung cancer, melanoma, renal cell carcinoma, and gastrointestinal cancers. The drug aims to expand the therapeutic window of CTLA-4 immunotherapy by optimizing safety and enhancing antitumor immune responses. Its cis-binding mechanism is intended to improve regulatory T-cell depletion in the tumor microenvironment[1][4][5][6].